
    
      During Part A, each patient will participate for up to 30 weeks, which includes a Screening
      Period of 1 to â‰¤ 6 weeks, followed by a Baseline Visit and 24 weeks of double-blind
      treatment:

        -  Screening Period: 1 - 6 weeks.

        -  Double-Blind Treatment Period: 24 weeks.

      After completion of Part A, patients will continue in Part B for an additional 56 weeks:

        -  Open-Label Treatment Period: 52 weeks.

        -  Post-Treatment Safety Follow Up: 4 weeks.
    
  